(RTTNews) - Fennec Pharmaceuticals Inc. (FENC), Friday announced that the National Institute for Health and Care Excellence or NICE has recommended Pedmarqsi, intended for the prevention of Cisplatin-induced hearing loss in patients with localized, non-metastatic, solid tumors.
The pharmaceutical company added that the findings from two open-label, randomized Phase 3 trials, SIOPEL 6 and the Clinical Oncology Group Protocol ACCL0431 demonstrated around 50 percent reduction in the occurrence of cisplatin-induced hearing loss in patients treated with cisplatin and sodium thiosulfate.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
